

Public Health Emergency Medical Countermeasure Enterprise – PHEMCE Interagency Enterprise Goals

- Define/prioritize requirements for public health medical emergency countermeasures
- Coordinate research and late-stage product development and procurement activities addressing the requirements
- Establish deployment and use strategies for medical countermeasures held in the Strategic National Stockpile



Coordination of Medical Countermeasures Activities

Federal Government

Homeland Security Council
National Security Council
Interagency Working Groups
DHS, DHHS, DoD, Other Agencies

DHHS

Office of Public Health Emergency Preparedness NIH, FDA, CDC

NIH NIH BRCC



Biodefense: Complementary Roles within DHHS

CDC



Surveillance and Detection

■ Train Local Response Teams

■ Maintain Vaccine/Antimicrobial Stockpiles

NIH



■ Conduct Basic Research

■ Develop Medical Interventions

■ Develop Research Infrastructure

FDA



■ Regulatory Approval

- Vaccines

Therapeutics

- Diagnostics


Office of Public Health Emergency Preparedness




HHS-Wide Coordination



A Comprehensive Biodefense Research Agenda









Biodefense Countermeasures: Key Achievements

Smallpox

- More than 300 million doses of smallpox vaccine now available
- "Next-generation" vaccine (MVA) in advanced testing
- Antiviral drug development, e.g. oral cidofovir

Anthrax

- New vaccine (rPA) tested and procured under Project Bioshield
- Development of novel antitoxins, e.g. monoclonal/polyclonal antibodies



Biodefense Countermeasures: Key Achievements (continued)

Ebola

Vaccine in human trials at NIAID Vaccine Research Center

Botulinum Toxin


Development of vaccine and monoclonal/polyclonal antibodies

Influenza

Development of vaccines against potential pandemic strains



Expansion of Research Capacity for Emerging Infectious Diseases



- National Biocontainment Laboratories (BSL4) 2
- Regional Biocontainment Laboratories (BSL3) 13
- Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research 10
- New NIH Facilities 4





National Institute of Allergy and Infectious Diseases (NIAID)

http://www.niaid.nih.gov/

FOR IMMEDIATE RELEASE Wednesday, May 3, 2006


NIH Dedicates the C.W. Bill Young Center for Biodefense and Emerging Infectious Diseases



A new building focused on research on infectious diseases of global importance — those that occur naturally or that may be caused by agents intentionally released through an act of bioterrorism — was dedicated yesterday on the Bethesda, Maryland campus of the National Institutes of Health (NIH).



Medical Countermeasures Against Radiological and Nuclear Threats




Research Priorities:

- Basic and translational research
- Methods to measure radiation doses
- Focused product development
- Infrastructure for research and product development











Published in the Federal Register September, 2006




Draft

Public Health Emergency
Medical Countermeasures
Enterprise Strategy for
Chemical, Biological,
Radiological and Nuclear
Threats

"...HHS will continue to support a robust basic research program that will aim to develop broadspectrum solutions using flexible technologies that enable more flexible next generation interventional concepts..."



BioShield Stakeholders Workshop



Bioshield Stakeholders:

- Pharmaceutical and biotechnology industries
- Professional societies
- State and local public health organizations and emergency response planners
- Academic research and development community
- Public interest groups
- Other stakeholder federal agencies (such as the Department of Homeland Security and Department of Defense) and Congress

